目的建立测定人血浆和尿液中吡西卡尼的高效液相色谱质谱联用方法。方法以液液萃取法进行样品处理,以乙腈-乙酸铵(0。1‰甲酸)-水为流动相(血药浓度测定:25∶37。5∶37。5;尿液中药物浓度测定:35∶6∶59),等度洗脱,经WelchMaterialUltimateAQ-C18(2。1mm×100mm,3。5μm)色谱柱分离,流速0。35mL·min-1、柱温25℃、进样量5μL。电喷雾离子源,正离子模式,多反应监测扫描(MRM),用于定量分析的离子反应分别为m/z273。4→110。2(吡西卡尼)和m/z287。4→110。2(内标,甲基吡西卡尼)。结果本法测定吡西卡尼浓度的线性范围分别为1~1200μg·L-1(血浆),1~150mg·L-1(尿液),最低定量限分别为1μg·L-1(血浆),1mg·L-1(尿液),相关系数r值在0。9962~0。9991之间,提取回收率,基质效应,批内、批间精密度均满足药物浓度测定要求。临床药动学研究中,应用此法测定了人血浆和尿液吡西卡尼的浓度。结论本方法简便、准确、灵敏度高、重现性好,可以满足药动学研究中药物浓度测定的要求。
Abstract
OBJECTIVE To develop a sensitive and specific LC-MS/MS method for the determination of pilsicainide in human plasma and urine. METHODS The samples were processed by LLE(liquid-liquid extraction), acetonitrile-ammonium acetate(0.1‰ formic acid)-water was used as the mobile phase with isocratic elution(25∶37.5∶37.5 in plasma, 35∶6∶59 in urine), and separation was carried out on Welch Material Ultimate AQ-C18 column(2.1 00×100 mm, 3.5 μm) , setting the flow rate as 0.35 mL·min-1, the column temperature at 25 ℃. The injection volume was 5 μL. ESI under positive ion mode and multiple reaction monitoring scan(MRM) were used for quantitative analysis with m/z 273.4→110.2 for pilsicainide and m/z 287.4→110.2 for internal standard, methyl-pilsicainide. RESULTS The linear ranges of the calibration curves for pilsicainide were 1-1 200 μg·L-1 for plasma and 1-150 mg·L-1 for urine. The limitation of detection were 1 μg·L-1 for plasma and 1 mg·L-1 for urine. The correlation coefficient was between 0.996 2 and 0.999 1.The extraction recoveries, matrix effects, and intra-/ inter-assay precisions all met the requirements of pharmacokinetic studies. This approach was applied to determine pilsicainide concentrations in human plasma and urine in a clinical pharmacokinetic research. CONCLUSION This approach possesses convenience, accuracy, high sensitivity and good reproducibility, which can meet the requirements of pharmacokinetic studies.
关键词
吡西卡尼 /
高效液相色谱-质谱联用 /
血浆浓度 /
尿药浓度
{{custom_keyword}} /
Key words
pilsicainide /
HPLC-MS/MS /
plasma drug concentration /
urine drug concentration
{{custom_keyword}} /
中图分类号:
R917
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] KUMAGAI K, NAKASHIMA H, TOJO H, et al. Pilsicainide for atrial fibrillation . Drugs, 2006, 66(16): 2067-2073.[2] AISAKA K, HIDAKA T, INOMATA N, et al. N-(2,6-Dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate(SUN 1165): A new potent and long-acting antiarrhythmic agent . Arzneimittelforschung, 1985, 35(8): 1239-1245.[3] HAYASHI H, FUJIKI A, TANI M, et al. Different effects of class Ⅰc and Ⅲ antiarrhythmic drugs on vagotonic atrial fibrillation in the canine heart . J Cardiovasc Pharmacol, 1998, 31(1):101-107.[4] IWASA A, OKUMURA K, TABUCHI T, et al. Effects of pilsicainide and propafenone on vagally induced atrial fibrillation: Role of suppressant effect in conductivity . Eur J Pharmacol, 1998, 356(1): 31-40.[5] HIROTSU I, KIHARA T, NAKAMURA S, et al. General pharmacological studies on N-(2,6-dimethyphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 1st communication: Effect on the central nevous system . Arzneim-forschi/Drug Res, 1988,38(11):1398.[6] AISAKA K, HIDAKA T, HATTORI Y, et al. General pharmacological studies on N-(2,6-dimethyphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 3rd communication: Effect on cardiovascular system . Arzneim-forschi/Drug Res, 1988,38(11):1417.[7] INO T, ATARASHI H, SAITOH H, et al. Electrophysiologic and hemodynamic effect of SUN 1165 in patiens with supraventricular tachycardia . Jpn J Clin Pharmacol Ther, 1989,20(4):667-685.[8] TERAZAWA T, SUZUKI M, GOTO T, et al. Suppressive effect of SUN 1165 on suppravetricular tachycardia . Am Heart J, 1991,121:1437.[9] HUANG Z H. New anti-arrhythmic drug-pilsicainide . Chin J New Drugs Clin Rein(中国新药与临床杂志), 2012,31(7):377. SHIGA T, HASHIGUCHI M, URAE A, et al. Effect of cimetidine and probenecid on pilsicainide renal clearance in humans . Clin Pharmacol Ther, 2000, 67(3): 222-228. MICHI W, SHUICHI T, KOICHI S, et al. Pilsicainide in breast milk from a mother: Comparison with disopyramide and propafenone . Br J Clin Pharmacol, 2005, 59(1): 120-122. European Medicines Agency. Guideline on bioanalytical method validation . . http://www. ema. europa. eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf. ZHONG D F, LI G, LIU C X. Guidance on bioanalysis: Method validation and analysis of study samples(Draft) . Drug Evaluation Research(药物评价研究), 2011, 34(6): 409-415. HU C H, QIAO J C, MA R, et al. The effect of different anticoagulants on determination of FK506 blood concentration in liver transplant recipients and clinical significance.Laboratory Medicine(检验医学), 2010, 25(5):368-371.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家科技重大专项资助(2012ZX09303016);北京市科技成果转化和产业化项目统筹资金资助(2012年)(Z121100006112062)
{{custom_fund}}